MedTrace Logo

Novel Biomarkers of Non-IgE Immediate Hypersensitivity Drug Reactions

NCT07605806 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2026-05-26

No results posted yet for this study

Summary

The goal of this clinical trial is to investigate biomarkers of non-IgE-mediated immediate hypersensitivity reactions during infusion of intravenous vancomycin. The main question it aims to answer is:

• Identifying novel biomarkers in blood that occur during infusion reaction

Participants will:

* Have allergy skin testing for vancomycin
* Receive an infusion of vancomycin

Conditions

  • Healthy Volunteer
  • Hypersensitivity Reactions
  • Vancomycin

Interventions

DRUG

Vancomycin (IV)

single infusion of vancomycin in healthy volunteers

Sponsors & Collaborators

Principal Investigators

  • Melanie Dispenza, MD, PhD · Johns Hopkins University

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-05-21
Primary Completion
2027-05-30
Completion
2027-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07605806 on ClinicalTrials.gov